Reference health
Controlled Release Matrix Tablets of Olanzapine: Influence of Polymers on the In Vitro Release and Bioavailability
1 of 43 checkable references need attention · checked 2026-07-22
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
does not resolve to a known work10.1023/A:1015276028425
The 42 checked references that resolve
resolves10.1016/j.pnpbp.2005.04.037
Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study
resolves10.4088/JCP.0207e04
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
resolves10.1097/00007691-199706000-00011
Plasma Level Monitoring of Olanzapine in Patients With Schizophrenia
resolves10.1016/0378-4347(95)00061-M
Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection
resolves10.1055/s-2007-973836
A Study of Genetic (<i>CYP2D6</i> and <i>ABCB1</i>) and Environmental (Drug Inhibitors and Inducers) Variables That May Influence Plasma Risperidone Levels
resolves10.1111/j.1532-5415.2005.53418.x
Antipsychotic Medications and Drug‐Induced Movement Disorders Other Than Parkinsonism: A Population‐Based Cohort Study in Older Adults
resolves10.1111/j.1532-5415.2004.52604.x
Optimizing Atypical Antipsychotic Treatment Strategies in the Elderly
resolves10.1176/appi.ps.52.6.805
Using Drug Claims Data to Assess the Relationship of Medication Adherence With Hospitalization and Costs
resolves10.1185/030079908X253384
Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia
resolves10.1208/s12249-008-9108-y
Formulation, Release Characteristics and Bioavailability Study of Oral Monolithic Matrix Tablets Containing Carbamazepine
resolves10.1208/pt0804083
Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles
resolves10.1208/pt070378
Once-daily tablet formulation and in vitro release evaluation of cefpodoxime using hydroxypropyl methylcellulose: A technical note
resolves10.1208/ps050213
Wet granulation fine particle ethylcellulose tablets: Effect of production variables and mathematical modeling of drug release
resolves10.1208/s12249-007-9030-8
Controlled Release Matrix Tablets of Zidovudine: Effect of Formulation Variables on the In Vitro Drug Release Kinetics
resolves10.1016/j.ijpharm.2005.12.037
Development of a controlled release low dose class II drug-Glipizide
resolves10.1002/jps.2600521210
Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices
resolves10.1023/A:1011976615750
In Vitro Dissolution Profile Comparison—Statistics and Analysis of the Similarity Factor, f2
resolves10.1208/s12249-010-9380-5
In Vitro Release Kinetics and Bioavailability of Gastroretentive Cinnarizine Hydrochloride Tablet
resolves10.1208/s12248-008-9031-x
Development of a GC-MS Assay for the Determination of Fentanyl Pharmacokinetics in Rabbit Plasma after Sublingual Spray Delivery
resolves10.1208/s12249-007-9031-7
Development and Evaluation of Buccoadhesive Controlled Release Tablets of Lercanidipine
resolves10.1016/S0378-4347(99)00017-1
Determination of olanzapine in human breast milk by high-performance liquid chromatography with electrochemical detection
resolves10.1002/jps.2600531126
Kinetic Analysis of Blood Levels and Urinary Excretion in the Absorptive Phase after Single Doses of Drug
resolves10.1016/S0920-9964(01)00312-7
Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder
resolves10.1002/jps.2600690102
Role of Binders in Moisture-Induced Hardness Increase in Compressed Tablets and its effect on in Vitro Disintegration and Dissolution
resolves10.3109/03639040903025848
Formulation and evaluation of natural gum-based sustained release matrix tablets of flurbiprofen using response surface methodology
resolves10.1016/S0168-3659(00)00366-7
Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate
resolves10.1016/0168-3659(87)90035-6
A simple equation for description of solute release II. Fickian and anomalous release from swellable devices
resolves10.1016/0168-3659(87)90034-4
A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs
resolves10.1016/S0168-3659(99)00004-8
Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets1This manuscript represents the personal opinions of the authors and does not necessarily represent the views or policies of the FDA.1
resolves10.1021/js950359z
Influence of pH on the Release of Propranolol Hydrochloride from Matrices Containing Hydroxypropylmethylcellulose K4M and Carbopol 974
resolves10.1248/cpb.54.1091
Analysis of the Release Process of Phenylpropanolamine Hydrochloride from Ethylcellulose Matrix Granules III. Effects of the Dissolution Condition on the Release Process
resolves10.1021/mp034006h
Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification
The 5 references without a DOI — listed, not checked
no DOI — not checkedMartindale SS. The complete drug reference. 35th ed. London: The Pharmaceutical Press; 2008.
no DOI — not checkedFDA. Guidance for industry. Dissolution testing of immediate release solid oral dosage forms. Rockville; 1997.
no DOI — not checkedShargel L, Yu A. Bioavailability and bioequivalence. In: Shargel L, Yu AB (eds) Applied biopharmaceutics and pharmacokinetics, 4th ed. New York: McGraw-Hill Medical Publishing Company; 1999.
no DOI — not checkedRowe RC, Sheskey PJ, Owen SC. Handbook of pharmaceutical excipient. London: Pharmaceutical Press; 2006.
no DOI — not checkedPeppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60(4):110–1.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1208/s12249-010-9510-0"><img src="https://citestamp.com/citestamped/10.1208/s12249-010-9510-0/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1208/s12249-010-9510-0)